Journal article
Evidence for the coupling of G(q) protein to D-1-like dopamine sites in rat striatum: Possible role in dopamine-mediated inositol phosphate formation
Molecular pharmacology, v 48(6), pp 988-994
01 Dec 1995
PMID: 8848015
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The role of G proteins in mediating the coupling of D-1 dopamine receptors to inositol phosphate formation was investigated in rat brain striatum. Pertussis toxin-activated ADP-ribosylation (greater than or equal to 95%) did not affect the ability of the D-1 agonist SKF38393 to stimulate the generation of inositol phosphates in striatal slices. Stimulation of striatal membranes with dopamine in the presence of [S-35]GTP gamma S or [alpha-P-32]GTP increased guanine nucleotide binding to G alpha(s), G alpha(i), and G alpha(q), in a concentration-dependent fashion. The activation of G(alpha s) and G(alpha q) was mimicked by the D-1 agonist SKF38393 and blocked by the D-1 antagonist SCH23390. In contrast, the D-2/3 dopamine receptor agonist quinpirole stimulated guanine nucleotide binding to G(alpha i), and dopamine-stimulated activation of G(alpha i) was attenuated by the D-2 antagonist I-sulpiride. Furthermore, antisera directed against G(alpha s) or G(alpha q) but not G(alpha i), G(alpha o), or G(alpha q) precipitated specific D-1-like binding sites labeled with [H-3]SCH23390. The D-1-like receptors that coprecipitated with G(alpha s)- but not with G(alpha q) can be recognized by a specific D-1 dopamine receptor antibody. The data provide evidence to suggest that in addition to coupling to G(s)/adenylyl cyclase, D-1-like dopamine sites that couple to G(q) may mediate dopamine-stimulated formation of inositol phosphates in the rat striatum.
Metrics
8 Record Views
Details
- Title
- Evidence for the coupling of G(q) protein to D-1-like dopamine sites in rat striatum: Possible role in dopamine-mediated inositol phosphate formation
- Creators
- H Y WangA S UndieE Friedman
- Publication Details
- Molecular pharmacology, v 48(6), pp 988-994
- Publisher
- Amer Soc Pharmacology Experimental Therapeutics
- Number of pages
- 7
- Grant note
- R01NS029514 / NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS) DA06871 / NIDA NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA) P01DA006871 / NATIONAL INSTITUTE ON DRUG ABUSE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); European Commission NS29514 / NINDS NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:A1995TL65500005
- Scopus ID
- 2-s2.0-0029417327
- Other Identifier
- 991019184295004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Pharmacology & Pharmacy